Team of Medan attend Copcov investigators meeting in Bangkok, Thailand

International COPCOV investigators gathered in Bangkok on December 15–16 of 2022 to discuss study findings and make plans for the future. Dr. Ayodhia Pitaloka, Site Principal-Investigator in Medan, M.Ked(Ped), Sp.A(K), Ph.D (CTM), attended this meeting together with some of the main team. Investigators from Pakistan, Nepal, the United Kingdom, Africa, and other countries also attended this meeting in addition to team Medan. The largest international trial of COVID-19 prevention in the world is being run by MORU under the direction of co-PIs Prof. Sir Nick White and Dr. Will Schilling. It has been funded by the Wellcome Trust.

Prof. Mavuto Mukaka presented the COPCOV study findings on the first day. A risky business: COPCOV, bureaucracy & commercialization of the global clinical trial, a thorough and thought-provoking history of COPCOV by University of Oxford historian Dr. Janelle Winters, was the topic of the day’s ending presentation.

Last Day , participants engaged in a broad, thoughtful discussion of COPCOV following a review of COPCOV study results by Will Schilling and Dr James Callery, who noted that an examination of serious adverse events (SAEs) in the study reaffirmed the very reassuring safety of HCQ and CQ. Nick White noted the importance of this reassuring safety evidence, as the WHO living guideline that recommend against HCQ is based partly on the supposition that HCQ is poorly tolerated with side effects. After this, all researchers prepared to launch the publication.